120 related articles for article (PubMed ID: 32715951)
1. Optimal vancomycin dose in the treatment of
Ereshefsky BJ; Alrahmany D; El Nekidy WS; Pontiggia L; Ghazi IM
J Chemother; 2021 May; 33(3):165-173. PubMed ID: 32715951
[No Abstract] [Full Text] [Related]
2. Effect of oral vancomycin dose on outcomes in patients with Clostridioides difficile infection.
O'Donnell JN; Novak GM; Bratek BR; Singh G; Duru OO; Mitchell CL; Roddy KM; Bidell MR
Int J Antimicrob Agents; 2021 Apr; 57(4):106311. PubMed ID: 33621602
[TBL] [Abstract][Full Text] [Related]
3. Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship.
Harpe SE; Inocencio TJ; Pakyz AL; Oinonen MJ; Polk RE
Pharmacotherapy; 2012 Aug; 32(8):744-54. PubMed ID: 23307522
[TBL] [Abstract][Full Text] [Related]
4. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
[TBL] [Abstract][Full Text] [Related]
5. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection.
Lam SW; Bass SN; Neuner EA; Bauer SR
Int J Antimicrob Agents; 2013 Dec; 42(6):553-8. PubMed ID: 24103633
[TBL] [Abstract][Full Text] [Related]
6. Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?
Wang Y; Schluger A; Li J; Gomez-Simmonds A; Salmasian H; Freedberg DE
Clin Infect Dis; 2020 Dec; 71(9):2414-2420. PubMed ID: 31714955
[TBL] [Abstract][Full Text] [Related]
7. Initial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI).
Manthey CF; Dranova D; Christner M; Drolz A; Kluge S; Lohse AW; Fuhrmann V
Crit Care; 2019 Dec; 23(1):399. PubMed ID: 31815650
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection.
Pettit NN; DePestel DD; Fohl AL; Eyler R; Carver PL
Pharmacotherapy; 2015 Feb; 35(2):119-26. PubMed ID: 25689243
[TBL] [Abstract][Full Text] [Related]
9. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
[TBL] [Abstract][Full Text] [Related]
10. A preliminary study of bowel rest strategy in the management of Clostridioides difficile infection.
Sugimoto H; Yoshihara A; Yamamoto T; Sugimoto K
Sci Rep; 2020 Dec; 10(1):22061. PubMed ID: 33328505
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non-Fulminant Severe Clostridioides difficile Infection.
Vega AD; Heil EL; Blackman AL; Banoub M; Kristie Johnson J; Leekha S; Claeys KC
Pharmacotherapy; 2020 May; 40(5):398-407. PubMed ID: 32246501
[TBL] [Abstract][Full Text] [Related]
12. Impact of oral vancomycin treatment duration on rate of
Kwiatkowski D; Marsh K; Katz A; Papadopoulos J; So J; Major VJ; Sommer PM; Hochman S; Dubrovskaya Y; Arnouk S
Infect Control Hosp Epidemiol; 2024 Jun; 45(6):717-725. PubMed ID: 38288606
[TBL] [Abstract][Full Text] [Related]
13. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
14. Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.
Ganetsky A; Han JH; Hughes ME; Babushok DV; Frey NV; Gill SI; Hexner EO; Loren AW; Luger SM; Mangan JK; Martin ME; Smith J; Freyer CW; Gilmar C; Schuster M; Stadtmauer EA; Porter DL
Clin Infect Dis; 2019 May; 68(12):2003-2009. PubMed ID: 30256954
[TBL] [Abstract][Full Text] [Related]
15. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
16. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
Tieu JD; Williams RJ; Skrepnek GH; Gentry CA
J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
[TBL] [Abstract][Full Text] [Related]
17. Potential impact of removing metronidazole from treatment armamentarium of mild acute
Zilberman-Itskovich S; Youngster I; Lazarovitch T; Bondarenco M; Toledano L; Kachlon Y; Mengesha B; Strul N; Zaidenstein R; Marchaim D
Future Microbiol; 2019 Nov; 14():1489-1495. PubMed ID: 31913060
[No Abstract] [Full Text] [Related]
18. Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study.
Popovic N; Korac M; Nesic Z; Milosevic B; Urosevic A; Jevtovic D; Mitrovic N; Markovic A; Jordovic J; Katanic N; Barac A; Milosevic I
Eur J Clin Microbiol Infect Dis; 2018 Apr; 37(4):745-754. PubMed ID: 29299697
[TBL] [Abstract][Full Text] [Related]
19. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
Gentry CA; Campbell DL; Williams RJ
Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
